<code id='ECE794B7FF'></code><style id='ECE794B7FF'></style>
    • <acronym id='ECE794B7FF'></acronym>
      <center id='ECE794B7FF'><center id='ECE794B7FF'><tfoot id='ECE794B7FF'></tfoot></center><abbr id='ECE794B7FF'><dir id='ECE794B7FF'><tfoot id='ECE794B7FF'></tfoot><noframes id='ECE794B7FF'>

    • <optgroup id='ECE794B7FF'><strike id='ECE794B7FF'><sup id='ECE794B7FF'></sup></strike><code id='ECE794B7FF'></code></optgroup>
        1. <b id='ECE794B7FF'><label id='ECE794B7FF'><select id='ECE794B7FF'><dt id='ECE794B7FF'><span id='ECE794B7FF'></span></dt></select></label></b><u id='ECE794B7FF'></u>
          <i id='ECE794B7FF'><strike id='ECE794B7FF'><tt id='ECE794B7FF'><pre id='ECE794B7FF'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive